Perdoceo Education (PRDO) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
6 Aug, 2026Executive summary
Q2 2026 delivered strong operating results, with revenue up 1.8% to $213.4 million and net income rising 16.9% to $48 million, driven by growth at USAHS and CTU, while AIUS saw a slight decline.
Year-to-date operating income grew 14.4%, supported by disciplined expense management and stable enrollments.
The University of St. Augustine for Health Sciences, acquired in 2024, expanded program offerings and contributed significantly to growth.
Quarterly dividend increased by 13.3% to $0.17 per share, reflecting confidence in financial strength.
Balance sheet remains robust, supporting organic investments and capital returns.
Financial highlights
Q2 2026 net income was $48 million ($0.75 per diluted share), up from $41 million ($0.62 per share) year-over-year; adjusted EPS increased 19.4% to $0.80.
Q2 revenue increased 1.8% to $213.4 million; year-to-date revenue up 3% to $435.1 million.
Operating income grew 6.8% to $54.9 million; adjusted operating income rose 4.4% to $64.2 million.
Cash, cash equivalents, and short-term investments totaled $734.8 million as of June 30, 2026.
Dividend payments increased to $0.17 per share for Q3 2026; $19.7 million paid in dividends YTD.
Outlook and guidance
Full-year 2026 adjusted operating income expected between $258 million and $263 million, up from $237.6 million in 2025.
Adjusted EPS guidance for 2026 is $3.10–$3.16, a 19.9% increase at midpoint over 2025.
Q3 2026 adjusted operating income expected at $64–$65 million; adjusted EPS $0.73–$0.74.
Effective tax rate for 2026 projected at 23–24%.
Capital expenditures for 2026 expected at 1% of revenues.
Latest events from Perdoceo Education
- Revenue up 4.1%, net income up 23.6%, and strong enrollment growth at CTU and USAHS.PRDO
Q1 20268 Jul 2026 - Annual meeting covers director elections, compensation, incentive plan, and auditor ratification.PRDO
Proxy filing9 Apr 2026 - Director elections, compensation, incentive plan, and auditor ratification up for shareholder vote.PRDO
Proxy filing9 Apr 2026 - 2025 saw double-digit growth in revenue, income, and enrollments, with strong 2026 guidance issued.PRDO
Q4 202519 Feb 2026 - Revenue and net income fell, but strong CTU growth and a dividend hike signal confidence.PRDO
Q2 20242 Feb 2026 - Enrollment up 11%, revenue down 5.6%, margins and outlook improve; acquisition closing soon.PRDO
Q3 202414 Jan 2026 - Q1 2025 revenue up 26.6% to $213M, driven by USAHS acquisition and enrollment growth.PRDO
Q1 202526 Dec 2025 - Q4 2024 saw record revenue and operating income, with 2025 set for further growth post-acquisition.PRDO
Q4 202423 Dec 2025 - Annual meeting to vote on directors, pay, and auditor amid growth, governance, and ESG focus.PRDO
Proxy Filing2 Dec 2025